MAO-B-IN-46

MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM) . MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM) . MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance[1][2].

27052-20-6

12352005

H302-H315-H319-H335

Amylases; Monoamine Oxidase

Metabolic Enzyme/Protease; Neuronal Signaling

Metabolism-protein/nucleotide metabolism

Metabolic Disease; Inflammation/Immunology; Neurological Disease

C1=CC=C2C(=C1)C=C(C(=O)C3=CC=C(C=C3)Cl)O2

C15H9ClO2

256.68

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]Guglielmi P, et al. Design, synthesis, and biological activity of 2-aroylbenzofuran-3-ols and 2-aroylbenzofuran derivatives: A new route towards hMAO-B inhibition. Eur J Med Chem. 2025 Nov 5;297:117983.|[2]Ali I, et al. Potent α-amylase inhibitors and radical (DPPH and ABTS) scavengers based on benzofuran-2-yl (phenyl) methanone derivatives: Syntheses, in vitro, kinetics, and in silico studies. Bioorg Chem. 2020 Nov;104:104238.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W207699/

Reference compound1

No Development Reported

MAO-A; MAO-B